Cellerys is developing a novel MS therapy that utilizes immune tolerance mechanisms to enhance patient safety and tolerability. The company aims to improve treatment outcomes for multiple sclerosis patients by inducing specific immune responses that mitigate disease progression.
Funding
Funding not disclosed
Founders
Product
Problem
Current multiple sclerosis (MS) therapies often come with significant side effects and tolerability issues, limiting their long-term effectiveness and patient adherence. These treatments may broadly suppress the immune system, increasing the risk of infections and other complications.
Solution
Cellerys is developing a targeted MS therapy that leverages immune tolerance mechanisms to enhance patient safety and tolerability. This approach aims to induce specific immune responses that selectively dampen the autoimmune activity driving MS, while preserving overall immune function. By promoting immune tolerance, Cellerys seeks to mitigate disease progression and improve treatment outcomes for individuals living with multiple sclerosis. The therapy is designed to minimize the risk of systemic immunosuppression and associated adverse events.
Target Audience
The primary target audience includes individuals diagnosed with multiple sclerosis, as well as neurologists and healthcare providers specializing in MS treatment.
Features
- Induction of antigen-specific immune tolerance to myelin antigens
- Selective modulation of the immune response to reduce autoimmune activity in MS
- Preservation of overall immune function to minimize the risk of infections
- Enhanced safety and tolerability compared to traditional immunosuppressive therapies